An Observer-Blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years.

Trial Profile

An Observer-Blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Hepatitis B vaccine recombinant; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
  • Indications Anal intraepithelial neoplasia; Hepatitis B; Human papillomavirus infections; Penile cancer; Prostatic intraepithelial neoplasia
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jan 2009 Primary endpoint 'Seroconversion rate' has been met.
    • 01 Jan 2009 Results reported in the Journal of Adolescent Health.
    • 21 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top